[Morphokinetic activity of chlormadinone acetate on hypothalamic and amygdaloid body neurons].

A. Smollich,A. Liske,M. Noack,H. Sajonski

1985-05-01

Abstract:

What problem does this paper attempt to address?

Modeling of in vitro drug release from polymeric microparticle carriers

Ljiljana Đekić,Ana Ćirić

DOI: https://doi.org/10.5937/arhfarm72-40229

2022-01-01

Arhiv za farmaciju

Abstract:Incorporation of active substances in polymeric microparticles (microencapsulation) is an important technological strategy used in the pharmaceutical industry to improve the functionality, quality, safety and/or therapeutic efficiency of pharmaceutical preparations for different routes of administration. The current focus of research in this field is on the encapsulation of small molecules and macromolecules into microparticles based on biocompatible synthetic polymers and biopolymers, such as polypeptides and polysaccharides, in order to achieve preferable drug release kinetics and many other advantages. Diversity in the structure and size of microparticles, choice of polymers, and manufacturing processes, allows for designing a multitude of microcarriers (e.g., monolithic matrix microspheres, hollow microcapsules, water-or oil-core microcapsules, stimulus-sensitive microcapsules), whereby their impact on biopharmaceutical profile of drugs can be manipulated. The results so far indicate that the in vitro drug release kinetics evaluation is one of the key aspects of the microparticle-type carrier characterization, where the application of the mathematical analysis (modeling) of the drug release profiles is an important tool for elucidating drug release mechanisms, as well as for evaluating the influence and optimization of formulation and process parameters in the microencapsulation procedure. The article reviews representative studies in which mathematical modeling of experimentally obtained release data was performed for microencapsulated model drugs with different physicochemical properties, as well as the relevance and potential limitations of this approach.
Increased Vesicular γ‐GABA Transporter and Decreased Phosphorylation of Synapsin I in the Rostral Preoptic Area is Associated with Decreased Gonadotrophin‐Releasing Hormone and c‐Fos Coexpression in Middle‐Aged Female Mice

Jing Zhang,L. Yang,X. Pan,N. Lin,X. C. Chen

DOI: https://doi.org/10.1111/jne.12050

2013-08-01

Journal of Neuroendocrinology

Abstract:Hypothalamic glutamate (Glu) and γ‐GABA neurotransmission are involved in the ovarian hormone‐induced gonadotrophin‐releasing hormone (GnRH)/luteinising hormone (LH) surge in rodents. Studies have shown that reduced Glu and increased γ‐GABA in the rostral preoptic area (rPOA) of the hypothalamus, where most activated GnRH neurones are located, play a key role in decreasing the reproductive function of female rats. However, the mechanism underlying the altered balance of these neurotransmitters is poorly understood. In the present study, we observed a decline in the function of GnRH neurones in the rPOA at the time of the GnRH/LH surge in middle‐aged intact female mice with regular oestrous cycles. In young mice, there is an increase of vesicular Glu transporter 2 on the pro‐oestrus afternoon, which is not observed in middle‐aged mice. By contrast, vesicular γ‐GABA transporter levels in young mice decrease at the time of the LH surge, whereas they increase in middle‐aged mice. Of note, we found that, in middle‐aged mice at the time of the GnRH/LH surge, the phosphorylation of synapsin I at Ser603 and Ca2+/calmodulin‐dependent kinase IIα was significantly lower than in young mice. These data suggest that, in middle‐aged mice, higher levels of presynaptic stores of GABA, a lack of increase of Glu and a decreased ability of synaptic vesicle mobilisation could account for the imbalance of Glu and GABA in the rPOA, which decreases the activation of GnRH neurones.
3D printed PLGA implants: How the filling density affects drug release

C Bassand,F Siepmann,L Benabed,J Verin,J Freitag,S Charlon,J Soulestin,J Siepmann

DOI: https://doi.org/10.1016/j.jconrel.2023.09.020

Abstract:Different types of ibuprofen-loaded, poly (D,L lactic-co-glycolic acid) (PLGA)-based implants were prepared by 3D printing (Droplet Deposition Modeling). The theoretical filling density of the mesh-shaped implants was varied from 10 to 100%. Drug release was measured in agarose gels and in well agitated phosphate buffer pH 7.4. The key properties of the implants (and dynamic changes thereof upon exposure to the release media) were monitored using gravimetric measurements, optical microscopy, Differential Scanning Calorimetry, Gel Permeation Chromatography, and Scanning Electron Microscopy. Interestingly, drug release was similar for implants with 10 and 30% filling density, irrespective of the experimental set-up. In contrast, implants with 100% filling density showed slower release kinetics, and the shape of the release curve was altered in agarose gels. These observations could be explained by the existence (or absence) of a continuous aqueous phase between the polymeric filaments and the "orchestrating role" of substantial system swelling for the control of drug release. At lower filling densities, it is sufficient for the drug to be released from a single filament. In contrast, at high filling densities, the ensemble of filaments acts as a much larger (more or less homogeneous) polymeric matrix, and the average diffusion pathway to be overcome by the drug is much longer. Agarose gel (mimicking living tissue) hinders substantial PLGA swelling and delays the onset of the final rapid drug release phase. This improved mechanistic understanding of the control of drug release from PLGA-based 3D printed implants can help to facilitate the optimization of this type of advanced drug delivery systems.
Modulating Drug Release from Short Poly(ethylene Glycol) Block Initiated Poly(L-lactide) Di-block Copolymers

Zein Azhari,Patricia Smith,Sean McMahon,Wenxin Wang,Ruth E. Cameron

DOI: https://doi.org/10.1007/s11095-022-03228-8

IF: 4.58

2023-01-01

Pharmaceutical Research

Abstract:This paper investigates drug release from a novel series of mPEG-functionalised PLLA polymers whose individual components (PEG and PLLA) have regulatory FDA approval. Two processing methods were explored to understand their effect on the morphology and drug release profiles of the polymers, with and without mPEG functionalisation. In the first method the polymer and Propranolol.HCl drug powders were mixed together before injection moulding. In the second method, supercritical CO2 was used to mix the polymer and drug before injection moulding. When non-functionalised PLLA was processed through injection moulding alone, there were no signs of polymer-drug interaction, and the drug was confined to crystals on the surface. This resulted in up to 85 wt% burst release of propranolol.HCl after one day of incubation. By contrast, injection moulding of mPEG-functionalised polymers resulted in the partial dissolution of drug in the polymer matrix and a smaller burst (50 wt% drug) followed by sustained release. This initial burst release was completely eliminated from the profile of mPEG-functionalised polymers processed via supercritical CO2. The addition of mPEG facilitated the distribution of the drug into the bulk matrix of the polymer. Paired with supercritical CO2 processing, the drug release profile showed a slow, sustained release throughout the 4 months of the study.
Surfactant Mediated Accelerated and Discriminatory In Vitro Drug Release Method for PLGA Nanoparticles of Poorly Water-Soluble Drug

Ritu Gupta,Yuan Chen,Mahua Sarkar,Huan Xie

DOI: https://doi.org/10.3390/ph15121489

IF: 4.6

2022-12-01

Pharmaceuticals

Abstract:In vitro drug release testing is an important quality control tool for formulation development. However, the literature has evidence that poly-lactide-co-glycolide (PLGA)-based formulations show a slower in vitro drug release than a real in vivo drug release. Much longer in vitro drug release profiles may not be reflective of real in vivo performances and may significantly affect the timeline for a formulation development. The objective of this study was to develop a surfactant mediated accelerated in vitro drug release method for the PLGA nanoparticles (NPs) of a novel chemotherapeutic agent AC1LPSZG, a model drug with a poor solubility. The Sotax USP apparatus 4 was used to test in vitro drug release in a phosphate buffer with a pH value of 6.8. The sink conditions were improved using surfactants in the order of sodium lauryl sulfate (SLS) < Tween 80 < cetyltrimethylammonium bromide (CTAB). The dissolution efficiency (DE) and area under the dissolution curve (AUC) were increased three-fold when increasing the CTAB concentration in the phosphate buffer (pH 6.8). Similar Weibull release kinetics and good linear correlations (R2~0.99) indicated a good correlation between the real-time in vitro release profile in the phosphate buffer (pH 6.8) and accelerated release profiles in the optimized medium. This newly developed accelerated and discriminatory in vitro test can be used as a quality control tool to identify critical formulation and process parameters to ensure a batch-to-batch uniformity. It may also serve as a surrogate for bioequivalence studies if a predictive in vitro in vivo correlation (IVIVC) is obtained. The results of this study are limited to AC1LPSZG NPs, but a similar consideration can be extended to other PLGA-based NPs of drugs with similar properties and solubility profiles.

pharmacology & pharmacy,chemistry, medicinal
[Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes].

A. Viestenz,P. Martus,U. Schlötzer-Schrehardt,A. Langenbucher,C. Mardin

Klinische Monatsblätter für Augenheilkunde

Abstract:BACKGROUND Histological changes of, in particular, collagen and extracellular matrix after administration of topical prostaglandin F(2alpha)(PGF (2alpha)) analogues have been reported. In view of this observation, we investigated the influence of PGF(2alpha) analogues on the central corneal thickness. PATIENTS AND METHODS In a non-randomized, controlled, cross-sectional study, 403 eyes from 208 consecutive patients were examined: 149 eyes (normals/controls) and 79 with ocular hypertension (OHT), 119 eyes with primary open angle glaucoma (POAG) and 56 eyes with normal tension glaucoma (NTG). One experienced ophthalmologist measured the central corneal thickness (CCT) using ultrasound pachymetry (Tomey AL-2000, sequence of 5 measurements with an SD < 3 microm). The central corneal power was measured with the Zeiss keratometer. Depending on the topical treatment, the patients were classified into 4 groups: A) PGF(2alpha) analogues (n = 78), B) carbonic anhydrase inhibitors (n = 26), C) combination of PGF (2)(alpha) analogues and carbonic anhydrase inhibitors (n = 41), D) none of these drugs (n = 258). T tests and multiple linear regression analyses were used for statistical analysis. RESULTS CCT was decreased significantly (p < 0.01 each) in eyes treated with PGF(2alpha) analogues (group A: 529 +/- 34 microM), in comparison with the untreated and non-glaucomatous eyes (part of group D: 542 +/- 35 microM, n = 148), untreated glaucomatous/OHT eyes (part of group D: 563 +/- 37 microM, n = 110), eyes treated with carbonic anhydrase inhibitors (group B: 561 +/- 32 microm) and eyes with a topical application of both PGF (2)(alpha) analogues and carbonic anhydrase inhibitors (group C: 555 +/- 48 microM. No correlation was found between CCT and diagnosis (OHT, POAG, NTG, control), gender, central corneal power, and intraocular pressure in a multivariate analysis. CONCLUSIONS The present findings suggest that the topical application of prostaglandin F(2alpha) analogues onto the cornea reduces the central corneal thickness significantly. These changes might be attributed to effects of PGF(2alpha) analogues on the extracellular matrix of the corneal stroma via upregulation of matrix metalloproteinases. In clinical practice, corneal thinning under local PGF (2)(alpha) analogue treatment could result in underestimation of intraocular pressure levels as measured by applanation tonometry.
In-situ forming PLGA implants: Towards less toxic solvents

F Ramos,J-F Willart,C Neut,K Agossa,J Siepmann,F Siepmann

DOI: https://doi.org/10.1016/j.ijpharm.2024.124121

2024-05-25

Abstract:In-situ forming poly(lactic-co-glycolic acid) (PLGA) implants offer a great potential for controlled drug delivery for a variety of applications, e.g. periodontitis treatment. The polymer is dissolved in a water-miscible solvent. The drug is dissolved or dispersed in this solution. Upon contact with aqueous body fluids, the solvent diffuses into the surrounding tissue and water penetrates into the formulation. Consequently, PLGA precipitates, trapping the drug. Often, N-methyl-2-pyrrolidine (NMP) is used as a water-miscible solvent. However, parenteral administration of NMP raises toxicity concerns. The aim of this study was to identify less toxic alternative solvent systems for in-situ forming PLGA implants. Various blends of polyethylene glycol 400 (PEG 400), triethyl citrate (TEC) and ethanol were used to prepare liquid formulations containing PLGA, ibuprofen (as an anti-inflammatory drug) and/or chlorhexidine dihydrochloride (as an antiseptic agent). Implant formation and drug release kinetics were monitored upon exposure to phosphate buffer pH 6.8 at 37 °C. Furthermore, the syringeability of the liquids, antimicrobial activity of the implants, and dynamic changes in the latter's wet mass and pH of the release medium were studied. Importantly, 85:10:5 and 60:30:10 PEG 400:TEC:ethanol blends provided good syringeability and allowed for rapid implant formation. The latter controlled ibuprofen and chlorhexidine release over several weeks and assured efficient antimicrobial activity. Interestingly, fundamental differences were observed concerning the underlying release mechanisms of the two drugs: Ibuprofen was dissolved in the solvent mixtures and partially leached out together with the solvents during implant formation, resulting in relatively pronounced burst effects. In contrast, chlorhexidine dihydrochloride was dispersed in the liquids in the form of tiny particles, which were effectively trapped by precipitating PLGA during implant formation, leading to initial lag-phases for drug release.
Burst Release from In Situ Forming PLGA-Based Implants: 12 Effectors and Ways of Correction

Elena O. Bakhrushina,Polina S. Sakharova,Polina D. Konogorova,Victor S. Pyzhov,Svetlana I. Kosenkova,Alexander I. Bardakov,Irina M. Zubareva,Ivan I. Krasnyuk,Ivan I. Krasnyuk

DOI: https://doi.org/10.3390/pharmaceutics16010115

IF: 6.525

2024-01-17

Pharmaceutics

Abstract:In modern pharmaceutical technology, modified-release dosage forms, such as in situ formed implants, are gaining rapidly in popularity. These dosage forms are created based on a configurable matrix consisting of phase-sensitive polymers capable of biodegradation, a hydrophilic solvent, and the active substance suspended or dissolved in it. The most used phase-sensitive implants are based on a biocompatible and biodegradable polymer, poly(DL-lactide-co-glycolide) (PLGA). Objective: This systematic review examines the reasons for the phenomenon of active ingredient "burst" release, which is a major drawback of PLGA-based in situ formed implants, and the likely ways to correct this phenomenon to improve the quality of in situ formed implants with a poly(DL-lactide-co-glycolide) matrix. Data sources: Actual and relevant publications in PubMed and Google Scholar databases were studied. Study selection: The concept of the review was based on the theory developed during literature analysis of 12 effectors on burst release from in situ forming implants based on PLGA. Only those studies that sufficiently fully disclosed one or another component of the theory were included. Results: The analysis resulted in development of a systematic approach called the "12 Factor System", which considers various constant and variable, endogenous and exogenous factors that can influence the nature of 'burst release' of active ingredients from PLGA polymer-based in situ formed implants. These factors include matrix porosity, polymer swelling, LA:GA ratio, PLGA end groups, polymer molecular weight, active ingredient structure, polymer concentration, polymer loading with active ingredients, polymer combination, use of co-solvents, addition of excipients, and change of dissolution conditions. This review also considered different types of kinetics of active ingredient release from in situ formed implants and the possibility of using the "burst release" phenomenon to modify the active ingredient release profile at the site of application of this dosage form.

pharmacology & pharmacy
PLGA implants for controlled drug release: Impact of the diameter

C Bassand,J Freitag,L Benabed,J Verin,F Siepmann,J Siepmann

DOI: https://doi.org/10.1016/j.ejpb.2022.05.020

Abstract:The aim of this study was to better understand the importance of the diameter of poly(lactic-co-glycolic acid) (PLGA)-based implants on system performance, in particular the control of drug release. Different types of ibuprofen-loaded implants were prepared by hot melt extrusion using a Leistritz Nano 16 twin-screw extruder. Drug release was measured in well agitated phosphate buffer pH7.4 bulk fluid and in agarose gels in Eppendorf tubes or transwell plates. Dynamic changes in the implants' dry & wet mass, volume, polymer molecular weight as well as inner & outer morphology were monitored using gravimetric analysis, optical macroscopy, gel permeation chromatography and scanning electron microscopy. The physical states of the drug and polymer were determined by DSC. Also pH changes in the release medium were investigated. Irrespective of the type of experimental set-up, the resulting absolute and relative drug release rates decreased with increasing implant diameter (0.7-2.8 mm). Bi-phasic drug release was observed in all cases from the monolithic solutions (ibuprofen was dissolved in the polymer): A zero order release phase was followed by a final, rapid drug release phase (accounting for 80-90% of the total drug dose). The decrease in the relative drug release rate with increasing system diameter can be explained by the increase in the diffusion pathway lengths to be overcome. Interestingly, also the onset of the final rapid drug release phase was delayed with increasing implant diameter. This can probably be attributed to the higher mechanical stability of thicker devices, offering more resistance to substantial entire system swelling.
Preparation, Characterization And In Vitro Release Properties Of Ibuprofen-Loaded Microspheres Based On Polylactide, Poly(Epsilon-Caprolactone) And Their Copolymers

Kj Zhu,Y Li,Hl Jiang,H Yasuda,A Ichimaru,K Yamamoto,P Lecomte,R Jerome

DOI: https://doi.org/10.1080/02652040400026350

2005-01-01

Journal of Microencapsulation

Abstract:In this paper, ibuprofen was encapsulated into microspheres by oil-in-water (o/w) emulsion solvent evaporation method. Biodegradable polymers with certain compositions and characteristics such as polylactide (PLA), poly(epsilon-caprolactone) (PCL) and their block copolymer were used to prepare the microspheres. The results indicate that, under the same processing conditions, the drug entrapment efficiency was similar (similar to 80%) for microspheres prepared with PLA and P(LA-b-CL) (78.7/21.3 by mole), but it was only 25.4% for PCL microspheres. The in vitro drug release rate decreased in the order of PCL, P(LA-b-CL) (78.7/21.3 by mole) and PLA microspheres. PCL microspheres showed more serious burst release during the first day (almost 80%) than P(LA-b-CL) (50%) and PLA microspheres (18%). The complete ibuprofen release duration from the last two kinds of microspheres exceeded I month. Characterization of the microspheres by differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and polarized optical microscope (POM) revealed that ibuprofen was amorphous in PCL microspheres and partially crystalline in P(LA-h-CL) and PI-A microspheres. The different release behaviour of ibuprofen from the three kinds of microspheres could be attributed to the different crystallinity of the studied polymers and drug dispersion state in polymer matrices. All the above results suggest that the copolymer with a certain ratio of lactide to epsilon-caprolactone could have potential applications for long-term ibuprofen release.
The Effect of Ph on the Polymer Degradation and Drug Release from PLGA‐mPEG Microparticles

Jin Li,Guoqiang Jiang,Fuxin Ding

DOI: https://doi.org/10.1002/app.28122

IF: 3

2008-01-01

Journal of Applied Polymer Science

Abstract:In vitro degradation and drug release of poly (DL-lactide-co-glycolic acid)-methoxypoly(ethyleneglycol) (PLGA-mPEG) microparticles were performed through a dynamic monitoring process, to investigate the effect of degradation on drug release from microparticles and to elucidate the dominant factor that governed the drug release kinetics. Methotrexate (MTX), an antirheurnatic drug, was employed as the model drug. Drug release showed a triphasic pattern: an initial burst release followed by a lag period and subsequently a second burst release. The initial burst release was mainly caused by dissolution and diffusion of drugs at/near the surface of microparticles. During the following lag period, microparticles suffered little morphological changes, whereas the physicochemical changes of the polymer contributed to the increasing mobility of drug molecules, and then provided transport pathways for drug release. Later on, the erosion of the polymer matrix became significant. Morphology study showed that the trend of porosity change was in accordance with last phase release profile, indicating that porosity played an extremely important role in controlling drug release. The liberation pattern of mPEG was elucidated. The more pores formed, the more mPEG chains were exposed to the aqueous medium and disengaged from the polymer. Scanning electron micrography observation further confirmed these conclusions. (C) 2008 Wiley Periodicals, Inc.
Preparation, characterization and in vitro release properties of ibuprofen-loaded microspheres based on polylactide, poly(ε-caprolactone) and their copolymers

KangJie Zhu,Yong Li,Hongliang Jiang,Hajime Yasuda,Akiko Ichimaru,K. Yamamoto,Philippe Lecomte,Robert J. Jérôme

DOI: https://doi.org/10.1080/02652040400026350

2008-01-01

Journal of Microencapsulation

Abstract:In this paper, ibuprofen was encapsulated into microspheres by oil-in-water (o/w) emulsion solvent evaporation method. Biodegradable polymers with certain compositions and characteristics such as polylactide (PLA), poly(epsilon-caprolactone) (PCL) and their block copolymer were used to prepare the microspheres. The results indicate that, under the same processing conditions, the drug entrapment efficiency was similar (similar to 80%) for microspheres prepared with PLA and P(LA-b-CL) (78.7/21.3 by mole), but it was only 25.4% for PCL microspheres. The in vitro drug release rate decreased in the order of PCL, P(LA-b-CL) (78.7/21.3 by mole) and PLA microspheres. PCL microspheres showed more serious burst release during the first day (almost 80%) than P(LA-b-CL) (50%) and PLA microspheres (18%). The complete ibuprofen release duration from the last two kinds of microspheres exceeded I month. Characterization of the microspheres by differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and polarized optical microscope (POM) revealed that ibuprofen was amorphous in PCL microspheres and partially crystalline in P(LA-h-CL) and PI-A microspheres. The different release behaviour of ibuprofen from the three kinds of microspheres could be attributed to the different crystallinity of the studied polymers and drug dispersion state in polymer matrices. All the above results suggest that the copolymer with a certain ratio of lactide to epsilon-caprolactone could have potential applications for long-term ibuprofen release.
Impact of PLGA molecular behavior in the feed solution on the drug release kinetics of spray dried microparticles

feng wan,jian x wu,adam bohr,stefania baldursdottir,morten jonas maltesen,simon bjerregaard,camilla foged,jukka rantanen,mingshi yang

DOI: https://doi.org/10.1016/j.polymer.2013.08.044

IF: 4.6

2013-01-01

Polymer

Abstract:The purpose of this study was to understand the impact of the poly (lactic-co-glycolic acid) (PLGA) molecular behavior in the feed solution on the drug release kinetics of PLGA microparticles prepared via spray drying. The PLGA molecular behavior in the feed solutions were characterized by using tube viscometry, which provides information about the polymer coil radius (Rcoil), the Martin constant (Km), and the overlap concentration (c*). The particle size and the drug surface enrichment were investigated by using scanning electron microscopy (SEM) and X-ray photoelectron spectroscopy (XPS), respectively. The drug release profiles were characterized by using the USP paddle method and analyzed by using the Crank's diffusion model to calculate the kinetic parameters. Multivariate data analysis using principal component analysis (PCA) was employed to display the relationship between the PLGA molecular behavior, particle properties and the drug release kinetics from the spray dried PLGA microparticles. Rheological studies suggested that an increased molar ratio of a poor solvent (methanol) in the solvent system resulted in a decreased Rcoil, the increase in Km and c*. The higher effective diffusion coefficient of drug calculated by using the Crank's diffusion model was observed in the polymer matrix prepared at an acetone-to-methanol molar ratio of 69:31. The PCA models indicated that the drug surface enrichment and the Km were directly proportional to the drug burst release, while the entanglement index was inversely correlated. Further, the particle size had a less significant impact on the drug burst release. This study implies that the polymer molecular behavior would influence the microscopic connectivity and diffusivity of polymer matrix, which eventually affects the drug release kinetics.
Poly(caprolactone)-Based Coatings on 3D-Printed Biodegradable Implants: A Novel Strategy to Prolong Delivery of Hydrophilic Drugs

Sarah A Stewart,Juan Domínguez-Robles,Victoria J McIlorum,Zoilo Gonzalez,Emilia Utomo,Elena Mancuso,Dimitrios A Lamprou,Ryan F Donnelly,Eneko Larrañeta

DOI: https://doi.org/10.1021/acs.molpharmaceut.0c00515

2020-09-08

Abstract:Implantable devices are versatile and promising drug delivery systems, and their advantages are well established. Of these advantages, long-acting drug delivery is perhaps the most valuable. Hydrophilic compounds are particularly difficult to deliver for prolonged times. This work investigates the use of poly(caprolactone) (PCL)-based implant coatings as a novel strategy to prolong the delivery of hydrophilic compounds from implantable devices that have been prepared by additive manufacturing (AM). Hollow implants were prepared from poly(lactic acid) (PLA) and poly(vinyl alcohol) (PVA) using fused filament fabrication (FFF) AM and subsequently coated in a PCL-based coating. Coatings were prepared by solution-casting mixtures of differing molecular weights of PCL and poly(ethylene glycol) (PEG). Increasing the proportion of low-molecular-weight PCL up to 60% in the formulations decreased the crystallinity by over 20%, melting temperature by over 4 °C, and water contact angle by over 40°, resulting in an increased degradation rate when compared to pure high-molecular-weight PCL. Addition of 30% PEG to the formulation increased the porosity of the formulation by over 50% when compared to an equivalent PCL-only formulation. These implants demonstrated in vitro release rates for hydrophilic model compounds (methylene blue and ibuprofen sodium) ranging from 0.01 to 34.09 mg/day, depending on the drug used. The versatility of the devices produced in this work and the range of release rates achievable show great potential. Implants could be specifically developed in order to match the specific release rate required for a number of drugs for a wide range of conditions.
Experiments and modeling of controlled release behavior of commercial and model polymer-drug formulations using dialysis membrane method

Alok Ranjan,Prateek K Jha

DOI: https://doi.org/10.1007/s13346-019-00696-1

Abstract:Standard dissolution testing methods typically do not correlate strongly with the in vivo drug release behavior for the oral delivery products, since they only focus on the drug dissolution in the gastric/intestinal fluid and do not account for the intestinal absorption of drug. Artificial gastrointestinal systems attempt to bridge this gap by using dialysis membranes as a proxy for the intestinal membranes. We present a systematic proof-of-concept study of how the drug dissolution and drug absorption are mimicked in such systems for the case of polymer-drug formulations. We utilize a modified version of the conventional shaking-flask test, in which the drug formulation is placed inside a dialysis bag. Dissolution experiments are performed on a commercial aspirin formulation and model formulations of aspirin with varying amounts of poly-methyl-methacrylate-co-methacrylic acid (PMA-MAA), both for conventional and modified shaking-flask test. Results are successfully interpreted using a simple model that assumes first-order kinetics for both the drug release from the formulation and drug permeation through the membrane. The differences between the model and commercial formulations and the effects of shaking speed and drug loading are established by comparison of the first-order rate constants. Finally, comparison with a reported in vivo study demonstrates how the modified shaking-flask setup can be used to improve the in vitro in vivo correlation. Graphical abstract.
Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings.

Jie Shen,Diane J Burgess

DOI: https://doi.org/10.1016/j.ijpharm.2011.10.020

IF: 6.51

2012-01-01

International Journal of Pharmaceutics

Abstract:Dexamethasone loaded poly(lactic-co-glycolic acid) (PLGA) microsphere/PVA hydrogel composites have been investigated as an outer drug-eluting coating for implantable devices such as glucose sensors to counter negative tissue responses to implants. The objective of this study was to develop a discriminatory, accelerated in vitro release testing method for this drug-eluting coating using United States Pharmacopeia (USP) apparatus 4. Polymer degradation and drug release kinetics were investigated under “real-time” and accelerated conditions (i.e. extreme pH, hydro-alcoholic solutions and elevated temperatures). Compared to “real-time” conditions, the initial burst and lag phases were similar using hydro-alcoholic solutions and extreme pH conditions, while the secondary apparent zero-order release phase was slightly accelerated. Elevated temperatures resulted in a significant acceleration of dexamethasone release. The accelerated release data were able to predict “real-time” release when applying the Arrhenius equation. Microsphere batches with faster and slower release profiles were investigated under “real-time” and elevated temperature (60°C) conditions to determine the discriminatory ability of the method. The results demonstrated both the feasibility and the discriminatory ability of this USP apparatus 4 method for in vitro release testing of drug loaded PLGA microsphere/PVA hydrogel composites. This method may be appropriate for similar drug/device combination products and drug delivery systems.
Correlative Image-Based Release Prediction and 3D Microstructure Characterization for a Long Acting Parenteral Implant

Zhen Liu,Li Li,Shawn Zhang,Josh Lomeo,Aiden Zhu,Jacie Chen,Stephanie Barrett,Athanas Koynov,Seth Forster,Peter Wuelfing,Wei Xu

DOI: https://doi.org/10.1007/s11095-021-03145-2

IF: 4.58

2021-11-01

Pharmaceutical Research

Abstract:Imaging-based characterization of polymeric drug-eluting implants can be challenging due to the microstructural complexity and scale of dispersed drug domains and polymer matrix. The typical evaluation via real-time (and accelerated in vitro experiments not only can be very labor intensive since implants are designed to last for 3 months or longer, but also fails to elucidate the impact of the internal microstructure on the implant release rate. A novel characterization technique, combining multi-scale high resolution three-dimensional imaging, was developed for a mechanistic understanding of the impact of formulation and manufacturing process on the implant microstructure. Artificial intelligence-based image segmentation and imaging analytics convert “visualized” structural properties into numerical models, which can be used to calculate key parameters governing drug transport in the polymer matrix, such as effective permeability. Simulations of drug transport in structures constructed on the basis of image analytics can be used to predict the release rates for the drug-eluting implant without running lengthy experiments. Multi-scale imaging approach and image-based characterization generate a large amount of quantitative structural information that are difficult to obtain experimentally. The direct-imaging based analytics and simulation is a powerful tool and has potential to advance fundamental understanding of drug release mechanism and the development of robust drug-eluting implants.

pharmacology & pharmacy,chemistry, multidisciplinary
[Unilateral hemothorax as sole clinical sign of kidney tumor].

R. Wieme

Abstract:
Characterization of degradation kinetics of additively manufactured PLGA under variable mechanical loading paradigms

Anna N Smith,Joseph B Ulsh,Richa Gupta,My My Tang,Ana P Peredo,Tim D Teinturier,Rob L Mauck,Sarah Gullbrand,Michael W Hast,Anna N. Smith,Joseph B. Ulsh,Ana P. Peredo,Tim D. Teinturier,Rob L. Mauck,Michael W. Hast

DOI: https://doi.org/10.1016/j.jmbbm.2024.106457

IF: 4.042

2024-05-01

Journal of the Mechanical Behavior of Biomedical Materials

Abstract:Controlled degradation of biodegradable poly-lactic-co-glycolic acid (PLGA) trauma implants may increase interfragmentary loading which is known to accelerate fracture healing. Additive manufacturing allows us to tune the mechanical properties of PLGA scaffolds; however, little is known about this novel approach. The purpose of this study was to use in vitro and in vivo models to determine the degradative kinetics of additively manufactured test coupons fabricated with PLGA. We hypothesized that 1) increases in infill density would lead to improved initial mechanical properties, and 2) loss of mechanical properties would be constant as a function of time, regardless of implant design. Porous and solid test coupons were fabricated using 85:15 PLGA filament. Coupons were either incubated in serum or implanted subcutaneously in rats for up to 16 weeks. Samples were tested in tension, compression, torsion, and bending on a universal test frame. Variables of interest included, but were not limited to: stiffness, and ultimate force for each unique test. Infill density was the driving factor in test coupon mechanical properties, whereas differences in lattice architecture led to minimal changes. We observed moderate levels of degradation after 8 weeks, and significant decreases for all specimens after 16 weeks. Results from this study suggest substantial degradation of 3-D printed PLGA implants occurs during the 8- to 16-week window, which may be desirable for bone fracture repair applications. This study represents initial findings that will help us better understand the complicated interactions between overall implant design, porosity, and implant biodegradation.

engineering, biomedical,materials science, biomaterials
The Influence of Shape Parameters on Unidirectional Drug Release from 3D Printed Implants and Prediction of Release from Implants with Individualized Shapes

Vanessa Domsta,Christin Hänsch,Stine Lenz,Ziwen Gao,Farnaz Matin-Mann,Verena Scheper,Thomas Lenarz,Anne Seidlitz

DOI: https://doi.org/10.3390/pharmaceutics15041276

IF: 6.525

2023-04-20

Pharmaceutics

Abstract:The local treatment of diseases by drug-eluting implants is a promising tool to enable successful therapy under potentially reduced systemic side effects. Especially, the highly flexible manufacturing technique of 3D printing provides the opportunity for the individualization of implant shapes adapted to the patient-specific anatomy. It can be assumed that variations in shape can strongly affect the released amounts of drug per time. This influence was investigated by performing drug release studies with model implants of different dimensions. For this purpose, bilayered model implants in a simplified geometrical shape in form of bilayered hollow cylinders were developed. The drug-loaded abluminal part consisted of a suitable polymer ratio of Eudragit® RS and RL, while the drug-free luminal part composed of polylactic acid served as a diffusion barrier. Implants with different heights and wall thicknesses were produced using an optimized 3D printing process, and drug release was determined in vitro. The area-to-volume ratio was identified as an important parameter influencing the fractional drug release from the implants. Based on the obtained results drug release from 3D printed implants with individual shapes exemplarily adapted to the frontal neo-ostial anatomy of three different patients was predicted and also tested in an independent set of experiments. The similarity of predicted and tested release profiles indicates the predictability of drug release from individualized implants for this particular drug-eluting system and could possibly facilitate the estimation of the performance of customized implants independent of individual in vitro testing of each implant geometry.

pharmacology & pharmacy

[Morphokinetic activity of chlormadinone acetate on hypothalamic and amygdaloid body neurons].

Modeling of in vitro drug release from polymeric microparticle carriers

Increased Vesicular γ‐GABA Transporter and Decreased Phosphorylation of Synapsin I in the Rostral Preoptic Area is Associated with Decreased Gonadotrophin‐Releasing Hormone and c‐Fos Coexpression in Middle‐Aged Female Mice

3D printed PLGA implants: How the filling density affects drug release

Modulating Drug Release from Short Poly(ethylene Glycol) Block Initiated Poly(L-lactide) Di-block Copolymers

Surfactant Mediated Accelerated and Discriminatory In Vitro Drug Release Method for PLGA Nanoparticles of Poorly Water-Soluble Drug

[Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes].

In-situ forming PLGA implants: Towards less toxic solvents

Burst Release from In Situ Forming PLGA-Based Implants: 12 Effectors and Ways of Correction

PLGA implants for controlled drug release: Impact of the diameter

Preparation, Characterization And In Vitro Release Properties Of Ibuprofen-Loaded Microspheres Based On Polylactide, Poly(Epsilon-Caprolactone) And Their Copolymers

The Effect of Ph on the Polymer Degradation and Drug Release from PLGA‐mPEG Microparticles

Preparation, characterization and in vitro release properties of ibuprofen-loaded microspheres based on polylactide, poly(ε-caprolactone) and their copolymers

Impact of PLGA molecular behavior in the feed solution on the drug release kinetics of spray dried microparticles

Poly(caprolactone)-Based Coatings on 3D-Printed Biodegradable Implants: A Novel Strategy to Prolong Delivery of Hydrophilic Drugs

Experiments and modeling of controlled release behavior of commercial and model polymer-drug formulations using dialysis membrane method

Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings.

Correlative Image-Based Release Prediction and 3D Microstructure Characterization for a Long Acting Parenteral Implant

[Unilateral hemothorax as sole clinical sign of kidney tumor].

Characterization of degradation kinetics of additively manufactured PLGA under variable mechanical loading paradigms

The Influence of Shape Parameters on Unidirectional Drug Release from 3D Printed Implants and Prediction of Release from Implants with Individualized Shapes